Proven results with COBENFY™

(xanomeline and trospium chloride)

Sagan is taking COBENFY and was compensated for his time.

COBENFY improved schizophrenia symptoms

Evaluated in three 5-week and two 52-week clinical studies involving more than 1250 adults with schizophrenia.

In 2 clinical studies,* COBENFY showed...
Proven significant symptom relief vs placebo (sugar pill)
Overall improvement
across a range of symptoms
Positive symptoms of schizophrenia: Like hallucinations and delusions. Negative symptoms of schizophrenia: Like lack of interest or emotion.
* A schizophrenia rating scale was used to compare meaningful changes in symptoms overall. These symptoms included positive, negative, and general psychopathology symptoms.
In 1 clinical study, COBENFY...
Reduced overall
severity of schizophrenia

Chanel is taking COBENY. Chanel and Fines were compensated for their time.

COBENFY was studied in two 5-week clinical studies with 470 adults aged 18 to 65 diagnosed with schizophrenia. Participants either took COBENFY or a sugar pill. Individual results may vary.

A different schizophrenia rating tool was used to evaluate meaningful overall changes in the severity of schizophrenia.

Get ready for your next appointment

Check out the COBENFY Discussion Guide to help you make the most of your next appointment with your healthcare provider.

Get support with COBENFY

Learn more about COBENFY Cares Champions,* available 24/7, 365 days a year.

* COBENFY Cares Champions are available to provide support to patients who have been prescribed COBENFY. Champions do not provide medical advice or care. COBENFY Cares Champions are provided as a service by Bristol Myers Squibb. Patients should discuss any questions about their medical conditions and treatment options with their healthcare providers.


1629-US-2501164  11/25

Cobenfy, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
© 2025 Bristol-Myers Squibb Company. 
1629-US-2500777 08/25
This website is intended for U.S. residents 18 years of age or older.